SLRN News and Press, ACELYRIN INC. From 04/04/25

Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and...

2025-04-03 12:22:51 ET Summary Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders PR Newswire NEW YORK , April 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential vi...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders PR Newswire NEW YORK , March 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential vi...

2025-03-13 08:02:56 ET More on Acelyrin Acelyrin: Potential Buyout Led By Concentra Biosciences Acelyrin falls after reaffirming Alumis deal Key deals this week: Howard Hughes, Shift4 Payments, Herc Holdings, Celsius and more Seeking Alpha’s Quant Rati...

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners’ continued rapid...

2025-03-12 04:59:08 ET Summary Concentra Biosciences' $3/share + CVR bid for SLRN is superior to the ALMS stock-for-stock offer, presenting us with a 20% spread in favor of its bid. SLRN's remaining Phase 2 asset, Lonigutamab, has shown disappointing results, making Concentra's ca...

2025-03-04 09:37:00 ET More on Alumis, Acelyrin, etc. Investors Looking To Durable Goods, New-Home Sales Data As Earnings Season Winds Down Acelyrin: Abandoned Programs Do Not Give Confidence Key deals this week: Howard Hughes, Shift4 Payments, Herc Holdings, Celsius...

SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clin...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge ...